
March 25 (Reuters) - Scholar Rock Holding Corp SRRK.O:
FDA GRANTS PRIORITY REVIEW FOR BIOLOGICS LICENSE APPLICATION (BLA) AND EMA ACCEPTS MARKETING AUTHORISATION APPLICATION (MAA) FOR APITEGROMAB AS A TREATMENT FOR SPINAL MUSCULAR ATROPHY
SCHOLAR ROCK HOLDING CORP - FDA PDUFA DATE FOR APITEGROMAB SET FOR SEPTEMBER 22, 2025
SCHOLAR ROCK HOLDING CORP - PLANS U.S. COMMERCIAL LAUNCH IN 2025